Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Kyle T. Bradley"'
Publikováno v:
Journal of Forensic Sciences. 67:387-390
Few cases of natural sudden death presenting as an undiagnosed lymphoma have been reported in the literature, especially in adolescents. Herein we provide a report of sudden death caused by undiagnosed classic Hodgkin lymphoma (cHL). We describe an 1
Publikováno v:
Seminars in Diagnostic Pathology. 34:371-376
The emergence of HIV/AIDS more than three decades ago led to an increased incidence of diseases caused by HHV8 co-infection, particularly Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Over time, the development of hig
Autor:
Kyle T. Bradley, Nisha Joseph, Madhav V. Dhodapkar, Craig C. Hofmeister, Shiyong Li, Sagar Lonial, Ajay K. Nooka, Jonathan L. Kaufman, Lawrence H. Boise
Publikováno v:
Blood. 136:50-51
Background: The clonoSEQ® Assay (Adaptive Biotechnologies; Seattle, WA) is an in vitro diagnostic that uses next-generation sequencing (NGS) to identify and quantify rearranged IgH (VDJ), IgH (DJ), IgK, and IgL receptor gene sequences, as well as tr
Autor:
Yue Xue, Volkan Adsay, Deniz Tuncel, Grace E. Kim, Ipek Erbarut, Michelle D. Reid, Kyle T. Bradley, Serdar Balci, Olca Basturk
Publikováno v:
International journal of surgical pathology. 28(3)
In the ampulla of Vater, carcinomas with “diffuse-infiltrative”/“signet ring cell” morphology, designated as “poorly cohesive carcinoma” (PCC) in the WHO classification, are very rare and poorly characterized. Nine cases with a classical
Autor:
Olga K. Weinberg, Genevieve M. Crane, James R. Cook, Sonam Prakash, Rachel L. Sargent, Kyle T. Bradley, Lorinda Soma, Dan Jones, Rose Beck, Flavia G. Rosado, Alexa J. Siddon, Steven H. Swerdlow, David Wu, Sarah E. Gibson, Annette S. Kim, Alexandra E. Kovach
Publikováno v:
American journal of clinical pathology. 152(4)
Objectives Given the increased complexity of molecular and cytogenetic testing (MOL-CG), the Society for Hematopathology Education Committee (SH-EC) was interested in determining what the current expectations are for MOL-CG education in hematopatholo
Autor:
Natia Esiashvili, Mary Jo Lechowicz, Jeffrey M. Switchenko, Kyle T. Bradley, T.R. Heumann, Christopher R. Flowers, H. Danish, Mohammad K. Khan
Publikováno v:
Dermatology and Therapy
Introduction Rotational total skin electron irradiation (RTSEI) is an effective therapy for cutaneous T cell lymphoma (CTCL). CD30 expression has been identified as a prognostic factor in CTCL. Therefore, we investigated CD30 status, treatment respon
Autor:
Debra Saxe, Charles E. Hill, David L. Jaye, Kyle T. Bradley, George Deeb, Linsheng Zhang, Shiyong Li, Karen P. Mann
Publikováno v:
Archives of pathologylaboratory medicine. 141(3)
Accurate assessment of tissues for hematolymphoid neoplasms requires an integrated multiparameter approach. Although morphologic examination by light microscopy remains the mainstay of initial assessment for hematolymphoid neoplasms, immunophenotypic
Autor:
Douglas A. Murphy, Christopher R. Flowers, Kyle T. Bradley, Daniel A. Goldstein, Emmanuel Moss
Publikováno v:
The Annals of thoracic surgery. 102(1)
We present a 67-year-old patient who underwent robotic excision of a mobile left ventricular mass found incidentally on echocardiography. Intraoperative findings revealed a pedunculated mass infiltrating the interventricular septum, and the results o
Publikováno v:
Modern Pathology. 19:1310-1316
Significant intra- and interobserver variability exists in diagnosing and grading oral epithelial dysplasia. Mutations in the tumor-suppressor gene p16 are common in oral cavity dysplastic lesions, but whether immunohistochemical detection of the gen
Autor:
Jeffrey M. Switchenko, Christopher R. Flowers, Ashley D. Staton, Kyle T. Bradley, Jean L. Koff, Oscar Calzada, Jonathon B. Cohen
Publikováno v:
Blood. 128:4225-4225
Introduction: Prior series have identified CD30 expression by immunohistochemistry (IHC) is associated with improved overall survival (OS) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL; 5-year OS: 79% vs 59% in CD30(-) patient